Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 31, 2025. The filing serves to announce the Company's results of operations for the fiscal year ended December 31, 2024. The Company's common stock trades on The Nasdaq Capital Market under the symbol "COCP."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K acts as a notification that a press release containing these details has been issued. The specific financial data is contained in Exhibit 99.1 (Press Release dated March 31, 2025), which is furnished but not included in the text of this filing.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the text provided. It references the press release for the full disclosure of the fiscal year 2024 results.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the body of this Form 8-K. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2025) for actual revenue, net loss, and cash position figures for the fiscal year ended December 31, 2024.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of any outstanding debt or financing arrangements referenced in the full financial results.